221 related articles for article (PubMed ID: 35477522)
21. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.
Rosanò L; Spinella F; Di Castro V; Dedhar S; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2006 Apr; 5(4):833-42. PubMed ID: 16648553
[TBL] [Abstract][Full Text] [Related]
22. Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.
Teoh JP; Park KM; Wang Y; Hu Q; Kim S; Wu G; Huang S; Maihle N; Kim IM
Cell Signal; 2014 Dec; 26(12):2885-95. PubMed ID: 25194819
[TBL] [Abstract][Full Text] [Related]
23. The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.
Del Rio D; Masi I; Caprara V; Ottavi F; Albertini Petroni G; Salvati E; Trisciuoglio D; Giannitelli SM; Bagnato A; Mauri E; Spadaro F; Rosanò L
Cell Death Dis; 2024 May; 15(5):358. PubMed ID: 38777849
[TBL] [Abstract][Full Text] [Related]
24. Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.
Semprucci E; Tocci P; Cianfrocca R; Sestito R; Caprara V; Veglione M; Castro VD; Spadaro F; Ferrandina G; Bagnato A; Rosanò L
Oncogene; 2016 Jun; 35(26):3432-42. PubMed ID: 26522724
[TBL] [Abstract][Full Text] [Related]
25. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
26. Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.
Tocci P; Caprara V; Cianfrocca R; Sestito R; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2016 Aug; 159():49-54. PubMed ID: 26776837
[TBL] [Abstract][Full Text] [Related]
27. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.
Rosanò L; Cianfrocca R; Tocci P; Spinella F; Di Castro V; Spadaro F; Salvati E; Biroccio AM; Natali PG; Bagnato A
Oncogene; 2013 Oct; 32(42):5066-77. PubMed ID: 23208497
[TBL] [Abstract][Full Text] [Related]
28. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Semprucci E; Di Castro V; Caprara V; Ferrandina G; Sacconi A; Blandino G; Bagnato A
Oncotarget; 2016 Jan; 7(4):4009-23. PubMed ID: 26675258
[TBL] [Abstract][Full Text] [Related]
29. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.
Dai Y; Wu Z; Lang C; Zhang X; He S; Yang Q; Guo W; Lai Y; Du H; Peng X; Ren D
Theranostics; 2019; 9(21):6063-6079. PubMed ID: 31534537
[No Abstract] [Full Text] [Related]
30. Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.
Rosanò L; Cianfrocca R; Sestito R; Tocci P; Di Castro V; Bagnato A
Expert Opin Ther Targets; 2017 Oct; 21(10):925-932. PubMed ID: 28758529
[TBL] [Abstract][Full Text] [Related]
31. miRNA‑199b‑3p suppresses growth and progression of ovarian cancer via the CHK1/E‑cadherin/EMT signaling pathway by targeting ZEB1.
Wei L; He Y; Bi S; Li X; Zhang J; Zhang S
Oncol Rep; 2021 Feb; 45(2):569-581. PubMed ID: 33416170
[TBL] [Abstract][Full Text] [Related]
32. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Di Castro V; Caprara V; Bagnato A
Life Sci; 2016 Aug; 159():43-48. PubMed ID: 26776834
[TBL] [Abstract][Full Text] [Related]
33. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.
Ibrahim HM; Abdelrahman AE; Elsebai E; Gharieb SA; Fahmy MM; Ramadan MSH; Wasfy MA; Abdullatif A
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3247-3259. PubMed ID: 37774079
[TBL] [Abstract][Full Text] [Related]
35. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
36. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
[TBL] [Abstract][Full Text] [Related]
37. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.
Larsen JE; Nathan V; Osborne JK; Farrow RK; Deb D; Sullivan JP; Dospoy PD; Augustyn A; Hight SK; Sato M; Girard L; Behrens C; Wistuba II; Gazdar AF; Hayward NK; Minna JD
J Clin Invest; 2016 Sep; 126(9):3219-35. PubMed ID: 27500490
[TBL] [Abstract][Full Text] [Related]
38. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
Zhang YL; Xia XK; Zhang M
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
[No Abstract] [Full Text] [Related]
39. Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma.
Han KS; Li N; Raven PA; Fazli L; Ettinger S; Hong SJ; Gleave ME; So AI
Mol Cancer Ther; 2015 Apr; 14(4):1024-34. PubMed ID: 25657336
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1.
Wu Y; Zhu B; Yan Y; Bai S; Kang H; Zhang J; Ma W; Gao Y; Hui B; Li R; Zhang X; Ren J
Mol Oncol; 2021 May; 15(5):1584-1596. PubMed ID: 33641229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
